- Home
- IGI vs MCRB Comparison
IGI vs MCRB Comparison
Compare IGI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGI | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.0M | 85.7M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IGI | MCRB |
|---|---|---|
| Price | $16.07 | $8.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 12.4K | ★ 36.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.78 | $6.64 |
| 52 Week High | $17.09 | $29.98 |
Technical Indicators
Market Signals| Indicator | IGI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 38.24 |
| Support Level | $15.78 | $8.08 |
| Resistance Level | $16.59 | $9.53 |
| Average True Range (ATR) | 0.14 | 0.54 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 24.61 | 25.72 |
Price Performance
Historical ComparisonAbout IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.